IEZZI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 1.578
EU - Europa 1.490
AS - Asia 929
SA - Sud America 115
AF - Africa 17
OC - Oceania 1
Totale 4.130
Nazione #
US - Stati Uniti d'America 1.554
RU - Federazione Russa 753
SG - Singapore 370
CN - Cina 246
IE - Irlanda 129
IT - Italia 116
VN - Vietnam 116
SE - Svezia 110
DE - Germania 101
BR - Brasile 83
FR - Francia 80
UA - Ucraina 75
TR - Turchia 72
GB - Regno Unito 55
IN - India 36
HK - Hong Kong 31
AT - Austria 15
AR - Argentina 13
FI - Finlandia 12
CZ - Repubblica Ceca 10
MX - Messico 10
BD - Bangladesh 9
CA - Canada 9
IQ - Iraq 9
JP - Giappone 8
PL - Polonia 8
ZA - Sudafrica 7
CL - Cile 5
PY - Paraguay 5
RO - Romania 5
SA - Arabia Saudita 5
BE - Belgio 4
ES - Italia 4
LB - Libano 4
LT - Lituania 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
JO - Giordania 3
KE - Kenya 3
NL - Olanda 3
BO - Bolivia 2
ET - Etiopia 2
KR - Corea 2
OM - Oman 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
TN - Tunisia 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
GE - Georgia 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
MA - Marocco 1
NI - Nicaragua 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 4.130
Città #
Singapore 310
Chandler 238
Ashburn 147
San Jose 136
Dublin 128
Jacksonville 127
Dearborn 90
Beijing 72
Dallas 58
Houston 58
Princeton 52
Los Angeles 49
Munich 43
Izmir 41
Nanjing 39
Ho Chi Minh City 37
Hong Kong 30
Wilmington 28
Altamura 26
Chieti 26
New York 26
The Dalles 25
Ann Arbor 21
Santa Clara 21
Boardman 20
Dong Ket 20
Hanoi 18
Southend 16
Moscow 15
Orem 14
Cambridge 13
Kunming 13
São Paulo 13
London 12
Redondo Beach 12
Nanchang 10
Nuremberg 10
Washington 10
Atlanta 9
Brno 9
Pescara 9
Shenyang 9
Chicago 8
Denver 8
Frankfurt am Main 8
Stockholm 8
Vienna 8
Buffalo 7
Jiaxing 7
Norwalk 7
Tokyo 7
Warsaw 7
Brooklyn 6
Da Nang 6
Hefei 6
Mexico City 6
Montreal 6
Tianjin 6
Boston 5
Hebei 5
Helsinki 5
Johannesburg 5
Mumbai 5
Brussels 4
Chennai 4
Haiphong 4
Hyderabad 4
Manchester 4
Poplar 4
Tongling 4
Woodbridge 4
Zhengzhou 4
Amman 3
Amsterdam 3
Asunción 3
Falls Church 3
Hangzhou 3
Istanbul 3
Joinville 3
Miami 3
Perego 3
Phoenix 3
Pune 3
Querétaro 3
Rio de Janeiro 3
Rome 3
San Francisco 3
Savigliano 3
Tappahannock 3
Tashkent 3
Addis Ababa 2
Baghdad 2
Campinas 2
Cerveteri 2
Changsha 2
Charlotte 2
City of London 2
Council Bluffs 2
Curitiba 2
Dhaka 2
Totale 2.306
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 848
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 172
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 171
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 163
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 157
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 155
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 150
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 149
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 146
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 145
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 133
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 130
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 128
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 127
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 125
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 123
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 122
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 122
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 120
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 120
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 120
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 116
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 114
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 114
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 107
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 89
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 81
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 75
Totale 4.322
Categoria #
all - tutte 13.319
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.319


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 5 3 28
2021/2022142 0 6 0 33 6 4 6 8 9 4 15 51
2022/2023561 38 75 38 77 48 100 22 55 69 7 21 11
2023/2024268 31 13 17 11 19 99 38 5 6 10 3 16
2024/2025458 30 67 63 27 10 42 17 24 48 36 46 48
2025/20261.908 99 42 109 161 157 96 292 69 790 93 0 0
Totale 4.322